About PharmaBiome
PharmaBiome is a Healthcare company based in Schlieren (Switzerland) founded in 2015 by Manuel Banz and Tomas De Wouters. Microbiome-based live therapeutics are developed for intestinal diseases. PharmaBiome has raised $1.86 million across 4 funding rounds from investors including European Union, Thomas Meier and Patrik Forrer. Its chief executive, as recorded, is Tomas De Wouters. PharmaBiome offers products and services including Bacterial Consortia Technology and Microbiome Research Platform. Its focus areas include Life Sciences, Microbiome Therapeutics, Targeted Agents and Gastroenterology. Its legal entity is PharmaBiome AG.
Company details
PharmaBiome was founded in 2015 in Schlieren, Switzerland, within the biotechnology sector. Microbiome-based live therapeutics are developed to address intestinal diseases. The NicheMap platform is utilized to map microbiome activity, guiding the assembly of engineered bacterial consortia. These products are tailored for conditions including ulcerative colitis, graft-versus-host disease, non-alcoholic steatohepatitis, multiple sclerosis, and rheumatoid arthritis.
- Headquarters Schlieren, Switzerland
- Founders Manuel Banz, Tomas De Wouters
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pharmabiome.com
- Social LinkedIn X
- Legal Name Pharmabiome Ag
- Total Equity Funding$1.86M (USD)
in 4 rounds
- Latest Funding Round$1.86M (USD), Seed
Jun 2020
- InvestorsEuropean Union
& 4 more
Products & Services of PharmaBiome
PharmaBiome offers a comprehensive portfolio of products and services, including Bacterial Consortia Technology and Microbiome Research Platform.
Engineers bacterial mixes to restore gut functions for disease treatment.
Provides technologies for analyzing and producing intestinal bacteria consortia.
Funding Insights of PharmaBiome
PharmaBiome has successfully raised a total of $1.86M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $1.86 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.86M
- Total Rounds 4
- Last Round Seed — $1.86M
- First Round $134,703
(Jun 2016)
- Investors Count 5
All 4 funding rounds of PharmaBiome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $1.86M | Seed | – | Thomas Meier, Patrik Forrer | – |
| Jul 2018 | $58,424 | Grant | – | – | |
| Apr 2018 | $61,568 | Grant | – | – | |
| Jun 2016 | $134,703 | Grant | – | – |
5 investors in total: 3 institutional and 2 angel.
Investors in PharmaBiome
PharmaBiome has secured backing from 5 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include European Union, Thomas Meier and Patrik Forrer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
University backed startup accelerator | venturekick.ch | Schlieren, Switzerland | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
TM Thomas Meier | Angel investor focusing on Indian startups, background in tech and finance. | unknown_781b069f580a4998a | ||
PF Patrik Forrer | unknown_d1c48126827c4c678 |
Investor details for PharmaBiome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PharmaBiome
17 people are tracked at PharmaBiome (3 in leadership, 5 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Manuel Banz | Co-Founder & COO | Leadership |
Tomas De Wouters | Co-Founder & CEO | Leadership |
Florian Rosenthal | Head CMC And R&d Operations | Leadership |
Alexey Borichev | Director | Board & advisors |
Christophe Lacroix | Director | Board & advisors |
Gerhard Rogler | Scientific Advisor | Board & advisors |
Erich F. Greiner | Chairman | Board & advisors |
Cristina De Min | Director | Board & advisors |
Carmen Menzi | Lab Manager | Team |
Jolanda Minder | IP Strategist | Team |
Maria del Carmen Otz | Operations Assistant | Team |
Maria Del Rocío Huerta Nunez | Operations Assistant | Team |
Gabriel E. Leventhal | CSO & Lead, R&D | Team |
Matthias Hülsmann | Operational Team | Team |
Lukas Bethlehem | Operational Team | Team |
Sophie Mathys | Regulatory Manager | Team |
Dr. Lukas Bethlehem | Scientist | Team |
Complete people profiles for PharmaBiome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PharmaBiome
3 dated milestones of PharmaBiome across 5 years, from founding to its latest funding, stage changes and deals.
- Founded PharmaBiome is founded.
- Funding First funding round of $135K.
- Funding Latest funding round, Seed, of $1.9M.
Web traffic of PharmaBiome
Websites that share an audience with PharmaBiome (pharmabiome.com).
Websites whose visitors overlap most with PharmaBiome. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| trilliome.com | 100% | View details | |||
| gastroscience.ch | 97% | 680.7K | #13,188,114 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharmabiome
Complete news archive for PharmaBiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PharmaBiome
PharmaBiome was founded in 2015 and raised its 1st funding round 1 year after it was founded.
PharmaBiome is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Tomas De Wouters is the CEO of PharmaBiome, as recorded in our data. They have also founded this company.
PharmaBiome is a funded company, having raised a total of $1.86M across 4 funding rounds to date. The company's 1st funding round was a Grant of $134.7K, raised on Jun 2016.
PharmaBiome was founded in 2015 in Schlieren, Switzerland, within the biotechnology sector. Microbiome-based live therapeutics are developed to address intestinal diseases. The NicheMap platform is utilized to map microbiome activity, guiding the assembly of engineered bacterial consortia. These products are tailored for conditions including ulcerative colitis, graft-versus-host disease, non-alcoholic steatohepatitis, multiple sclerosis, and rheumatoid arthritis.
PharmaBiome offers Bacterial Consortia Technology and Microbiome Research Platform.
PharmaBiome has 5 investors. Key investors include European Union, Thomas Meier, Patrik Forrer, EIC Fund, and Venture Kick.
PharmaBiome operates through Pharmabiome Ag.